Partial suppression of type 2 inflammation with mepolizumab

J Allergy Clin Immunol Pract. 2022 Dec;10(12):3343. doi: 10.1016/j.jaip.2022.08.053.

Authors

Kirsten E Stewart¹, Rory Chan², Rasads Misirovs², Brian J Lipworth²

Affiliations

¹ Scottish Centre for Respiratory Research, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom. Electronic address: Kstewart004@dundee.ac.uk.
² Scottish Centre for Respiratory Research, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom.

PMID: 36496220
DOI: 10.1016/j.jaip.2022.08.053

No abstract available

Publication types

Letter
Comment

MeSH terms

Anti-Asthmatic Agents* / therapeutic use
Eosinophils
Humans

Substances

Anti-Asthmatic Agents